Clinical Trials in Tupelo, Mississippi
19 recruiting
Showing 1–19 of 19 trials
Recruiting
Phase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Novo Nordisk A/S1,280 enrolled285 locationsNCT07207811
Recruiting
Not Applicable
The CONFORM Pivotal Trial
Atrial FibrillationStroke
Conformal Medical, Inc1,600 enrolled83 locationsNCT05147792
Recruiting
Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Carcinoma, Non-Small Cell LungNeoplasm Metastasis
Eli Lilly and Company1,264 enrolled424 locationsNCT06119581
Recruiting
Phase 3
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
Heart Failure
Novo Nordisk A/S5,600 enrolled1117 locationsNCT05636176
Recruiting
Phase 1Phase 2
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
Staphylococcus Aureus
AstraZeneca231 enrolled41 locationsNCT06749457
Recruiting
Phase 3
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company920 enrolled303 locationsNCT07174336
Recruiting
Not Applicable
SPYRAL GEMINI Pilot Study
Diabetes MellitusCardiovascular DiseasesHypertension+2 more
Medtronic Vascular175 enrolled13 locationsNCT06907147
Recruiting
Phase 2Phase 3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
End-stage Kidney DiseaseAtherosclerotic Cardiovascular DiseaseAtherosclerotic Cardiovascular Disease in Patients With ESKD
CSL Behring2,310 enrolled468 locationsNCT05485961
Recruiting
Phase 2
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
Atrial Fibrillation
Novartis Pharmaceuticals165 enrolled30 locationsNCT07217067
Recruiting
Phase 3
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
Heart FailureAcute Heart Failure
Colorado Prevention Center5,200 enrolled80 locationsNCT06008197
Recruiting
Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Atrial Fibrillation (AF)
Anthos Therapeutics, Inc.1,900 enrolled721 locationsNCT05712200
Recruiting
Phase 2
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis
Gilead Sciences176 enrolled129 locationsNCT06029972
Recruiting
Phase 2
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
Proteinuric Kidney Disease
Maze Therapeutics56 enrolled74 locationsNCT06830629
Recruiting
Phase 3
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
HyperphosphatemiaDialysisChronic Kidney Disease, Receiving Dialysis+1 more
Alebund Pharmaceuticals264 enrolled42 locationsNCT06933472
Recruiting
Not Applicable
Assessment of CCM in HF With Higher Ejection Fraction
Heart FailureHeart Failure With Preserved Ejection FractionDiastolic Heart Failure+2 more
Impulse Dynamics1,500 enrolled112 locationsNCT05064709
Recruiting
Phase 3
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Chronic Kidney DiseasesType 2 Diabetes Mellitus
Prokidney685 enrolled86 locationsNCT05099770
Recruiting
Phase 3
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
Acute Coronary Syndrome
DalCor Pharmaceuticals2,000 enrolled223 locationsNCT05918861
Recruiting
Phase 2
Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities
Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated45 enrolled35 locationsNCT06794996
Recruiting
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
Obstructive Hypertrophic Cardiomyopathy
Bristol-Myers Squibb1,600 enrolled99 locationsNCT05489705